Inhibition of tumor growth and metastasis via local administration of recombinant human endostatin adenovirus

Chinese Journal of Medical Genetics

Volumn 21, Issue 6, 2004, Pages 557-561

  Wu, Yang ^a   Yang, Li ^a   Zhao, Xia ^a   Su, Jing Mei ^a   Hu, Bing ^a   Liu, Ji Yan ^a   Niu, Ting ^a   Luo, Yan ^a   Li, Qiu ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Adenovirus; Antiangiogenic gene therapy; Endostatin; Tumor

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; COLLAGEN TYPE 18; ENDOSTATIN; RECOMBINANT HUMAN ENDOSTATIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CULTURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOSTATINS; ENDOTHELIAL CELLS; GENE THERAPY; GENETIC VECTORS; HUMANS; KIDNEY; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RANDOM ALLOCATION; RECOMBINANT PROTEINS; TRANSFECTION; UMBILICAL VEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 10644272749     PISSN: 10039406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Folkman J. Clinical applications of research angiogenesis. N Engl J Med, 1995, 333: 1757-1763.
2. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferationand apoptosis in the presence of angiogenesis suppression. Nat Med, 1995, 1: 149-153.
3. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997, 88: 277-285.
4. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol, 2002, 20: 3792-3803.
5. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol, 2003, 21: 223-231.
6. Regulier E, Paul S, Marigliano M. Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach. Cancer Gene Ther, 2001, 8: 45-54.
7. Zhao X, Peng ZL, Zhao M, et al. Therapeutic effects of adenoviral vector-mediated endostatin gene transfer in malignant ascites. Chin J Modern Med, 2003, 13: 4-6
8. Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 1997, 390: 404-407.
9. Kerbel RS. A cancer therapy resistant to resistance. Nature, 1997, 390: 335-336.
10. Ding I, Sun JZ, Fenton B, et al. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res, 2001, 61: 526-531.
11. Yoon SS, Eto H, Lin CM, et al. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res, 1999, 59: 6251-6256.
12. Yamaguchi N, Anand-Apte B, Olsen BR, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J, 1999, 18: 4414-4423.
13. Mohanraj D, Ramani R, Matthew JF, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem, 1999, 274: 11721-11726.
14. Marko R, Tanja V, Eola KV. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A, 2001, 98: 1024-1029.
15. Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase2. Cancer Res, 2000, 60: 5410-5413.
16. Blezinger P, Wang J, Gondo M, et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol, 1999, 17: 343-348.
17. Sauter BV, Martinet O, Zhang WJ, et al. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci U S A, 2000, 97: 4802-4807.
18. Chen CT, Lin J, Li Q. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum Gene Ther, 2000, 11: 1983-1996.
19. Feldman AL, Restifo NP, Alexander HR. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res, 2000, 60: 1503-1506.
20. Wen XY, Bai Y, Stewart AK. Adenovirus-mediated human endostatin gene delivery demonstrates strain-specific antitumor activity and acute dose-dependent toxicity in mice. Hum Gene Ther, 2001, 12: 347-358.
21. Akporiaye ET, Hersh E. Clinical aspects of intratumoral gene therapy. Curr Opin Mol Ther, 1999, 4: 443-453.
22. Harvey BG, Maroni J, O'Donoghue KA, et al. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther, 2002, 13: 15-63.